LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Inicio・Lista de Acciones・Biogen Inc

Biogen Inc

Abierto

Sector Salud

200.49 0.2

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

198.03

Máximo

200.95

Métricas clave
By Trading Economics
Ingresos	190M 584M
Ventas	180M 2.5B
P/B Media del Sector	28.98 103.001
BPA	5.28
Margen de beneficio	23.628
Empleados	7,570
EBITDA	237M 919M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+37 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	122M 30B
Apertura anterior	200.29
Cierre anterior	200.49

Noticias sobre sentimiento de mercado

By Acuity

50%

100 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

198.19 / 204.86 Soporte y Resistencia

Biogen Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 sept 2024, 11:00 UTC

Principales Noticias

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 may 2024, 15:56 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4 oct 2023, 17:55 UTC

Adquisiciones, fusiones, absorciones

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

Comparación entre iguales

Cambio de precio

Biogen Inc Esperado

Precio Objetivo

By TipRanks

37% repunte

Estimación a 12 meses

Media 275.11 USD 37%

Máximo 342 USD

Mínimo 190 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Biogen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

198.19 / 204.86Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

100 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.